CHAMPION- AF

Clinical trial to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants (NOACs) in patients with non-valvular Atrial Fibrillation

Primary Inclusion	Primary Exclusion
❑ Age > 18 years old	❑ Requires long-term anticoagulation therapy for reasons other than AF-related stroke risk reduction
❑ Documented non-valvular atrial fibrillation (i.e. atrial fibrillation, in the absence of moderate or greater mitral stenosis or a mechanical heart valve)	❑ The subject had or is planning to have any cardiac or non cardiac intervention or surgical procedure within 30 days prior to or 60 days after implant (including, but not limited to: cardioversion, percutaneous coronary intervention, cardiac ablation, cataract surgery, etc.)
❑ The subject has a calculated CHA2DS2-VASc score of 2 or greater for men and 3 or greater for women	❑ Indicated for chronic P2Y12 platelet inhibitor therapy
❑ Suitable for the protocol defined pharmacologic regimens in both the test and control arms	❑ History of atrial septal repair or has an ASD/PFO device ❑ Subject has an implanted mechanical valve prosthesis in any position
	❑ LVEF < 30%

PI: Albert Lin, MD

Study Coordinator: Amy Carswell
Pager: 5-7501, Phone: 6-7554, amy.carswell@nm.org

Northwestern Medicine®